Michael A. Tortorici

Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study

Ezra E.W. Cohen, Lee S. Rosen, Everett E. Vokes et al. · Journal of Clinical Oncology · 2008 · 622 citations · Full text

Medicine, Oncology, Pharmacology +14

Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE)

Noel G. McElvaney, Jonathan Burdon, Mark Holmes et al. · The Lancet Respiratory Medicine · 2016 · 194 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +12

Mild Hypothermia Alters Midazolam Pharmacokinetics in Normal Healthy Volunteers

David Hostler, Jiangquan Zhou, Michael A. Tortorici et al. · Drug Metabolism and Disposition · 2010 · 85 citations · Full text

Medicine, Clinical Pharmacokinetics, Clinical Pharmacology +7

Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers

Yazdi K. Pithavala, Michael A. Tortorici, Melvin Toh et al. · Cancer Chemotherapy and Pharmacology · 2009 · 71 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +10

CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients

Andreas Gille, Denise D’Andrea, Michael A. Tortorici et al. · Arteriosclerosis Thrombosis and Vascular Biology · 2018 · 66 citations · Full text

Medicine, Cardiology, Pharmacology +17